Fuzheng Pharma revs up infusion production line
Shanghai. December 20. INTERFAX-CHINA - Gansu Fuzheng Pharmaceutical Technologies Co. Ltd. has started producing polypropylene (PP) bottle infusions at a new production line in Gansu Province's Dingxi City, local media reported Dec. 20.
According to Dingxi Daily, Fuzheng Pharma invested a total of RMB 100 million ($15.03 million) in the facility, which has production capacity for 100 million bottles annually and is projected to generate annual sales revenue of RMB 200 million ($30.06 million).
The workshop has Good Manufacturing Practice (GMP) certification from the local branch of the State Food and Drug Administration (SFDA), and is the first of its kind in Gansu.
In recent years non-polyvinyl chloride (non-PVC) and PP have been rapidly replacing glass as packaging material for infusions in China.
Fuzheng Pharma will target Gansu and neighboring provinces with the infusions, the report said.
Based in Dingxi City, Fuzheng Pharma is a leading traditional Chinese medicine (TCM) manufacturer in Gansu. The company produces sodium chloride, ofloxacin and glucose infusions, among others.